tirzepatide surmount 3 ECO 2026: SURMOUNT-MAINTAIN proves sustains weight loss long term Tirzepatide for the Maintenance of

This summary does not replace Patient Drug Education materials or official prescribing documentation

A 2023 analysis in Gastroenterology noted that GLP-1 agonists do not increase recurrent diverticulitis risk in patients with prior episodes, provided acute inflammation has completely resolved

It is distinct from Rybelsus, which is lower-dose oral semaglutide licensed for type 2 diabetes

Intestinal microbiota-derived short chain fatty acids in host health and disease

Wegovy, another drug by the same company which is not yet on sale in Greece, is used exclusively for the management of obesity, she says, while the injectable drug Ozempic has been approved by the US Food and Drug Administration as an anti-diabetic drug since 2017

Consult with your dietician to get a personalized diet plan for you